Efficacy of voriconazole on leishmaniasis by Leishmania major: An in vitro and in vivo study

• Main Authors: Ahmad Oryan, Somayeh Bahrami, Effat Bemani
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2018-01-01
• Series: Asian Pacific Journal of Tropical Medicine
• Subjects: leishmania major; wound healing; azoles; voriconazole; histopathology
• Online Access: http://www.apjtm.org/article.asp?issn=1995-7645;year=2018;volume=11;issue=10;spage=562;epage=569;aulast=Oryan

Objective: To appraise the activity of voriconazole against Leishmania major (L. major) in vitro and its effectiveness on wound regeneration in cutaneous leishmaniasis in BALB/c mice. Methods: The IC50 of voriconazole against promastigotes and intra-macrophage amastigotes of L. major was investigated in vitro. The in vivo study was performed by treating the L. major infected BALB/c mice. When the wounds appeared in the base of tail, treatment was started by administration of 30 mg/kg voriconazole for 28 consecutive days orally. Results: The IC50 of voriconazole against promastigotes and intra-macrophage amastigotes were 0.74 and 0.89 ģĢ, respectively. Voriconazole decreased lipid peroxidation and IL-6 level. Histopathological findings indicated accelerated healing in the voriconazole treated group compared to other groups. Conclusions: Our results demonstrate that voriconazole can be an option in treating the cutaneous leishmaniasis by L. major.